Aug. 7, 2013
Amgen Launches Post-Doctoral Fellowship Program in China
Supporting the Next Generation of Scientists and Biopharmaceutical Research in China
BEIJING, China, August 7, 2013 – Amgen today announced the launch of the Amgen China Post-Doctoral Fellowship Program. The program aims to promote biopharmaceutical research by supporting advanced training to doctoral-level scientists in China.
Amgen will award 10 post-doctoral fellowships at five leading academic institutions in China including Tsinghua University, Peking University, the National Institute of Biological Sciences, Shanghai Jiaotong University and ShanghaiTech University. Each post-doctoral fellowship will support two years of academic research at these five institutions.
Research projects have been selected based on their originality and impact on science. The research projects awarded under the 2013 program aim to explore the fundamental elements linked to the biology of certain diseases of which there is a growing prevalence in China.
“Globally Amgen has a strong commitment to supporting research and development in the biotechnology sector,” said Dr. Joe Miletich, Senior Vice President of Research & Development, Amgen. “We work to bring this philosophy to every market in which we operate and believe research and development is critical to the overall advancement of China’s biotechnology sector.”
“We hope the Post-Doctoral Program helps to develop an ecosystem of innovation in China by providing young talented scientists with opportunities for higher education in biotechnology,” Dr. Miletich added. “On behalf of Amgen I would like to thank our academic partners for their support.”
“The Post-Doctoral Program is a concrete step in Amgen’s efforts to establish a research and development footprint in China,” said Mingqiang Zhang, Vice President of Research & Development of Amgen China. “In the long-term, our Post-Doctoral Program will help us to connect with the growing network of centers of academic excellence in China. These will be at the forefront of scientific advancement related to both existing and future serious diseases prevalent among Chinese patients.”
“This is a great opportunity for China’s young scientists,” said Prof Yigong Shi, Dean of the School of Life Sciences, Tsinghua University. “Developing top young scientific talent is a key focus for both academic research and the entire biotechnology sector in China. The Amgen China Post-Doctoral Fellowship Program supports this goal by providing critical support to young scientists to undertake exploratory research and with the guidance of top scientists in China.”
“The Amgen Post-Doctoral Program supports independent biopharmaceutical research in China,” said Prof Xiaodong Wang, Director, National Institute of Biological Sciences. “This type of research plays a key role in advancing scientific understanding of the biology behind serious diseases and in developing critical research capabilities which will support the long-term development of China’s biotech sector.”
The program is an extension of Amgen’s longstanding commitment to supporting scientific education, including investing in fellowships with universities in the markets where Amgen operates.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information, visit http://wwwext.amgen.com and follow us on www.twitter.com/amgen.
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on Amgen’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen’s most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen’s most recent Form 10-K and any subsequent Forms 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen’s business. Unless otherwise noted, Amgen is providing this information as of May 9, 2013, and expressly disclaims any duty to update information contained in this news release.
No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen’s products after they are on the market. Amgen’s business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.
In addition, sales of Amgen’s products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of Amgen’s products. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen’s products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen’s ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen’s stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen’s products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen’s business and results of operations.
The scientific information discussed in this news release related to Amgen’s product candidates is preliminary and investigative. Such product candidates are not approved by the State Food and Drug Administration of the People’s Republic of China (SFDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only regulatory agencies such as the U.S. Food and Drug Administration and the SFDA can determine whether the product candidates are safe and effective for use in the applicable region. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this news release.
Mary Klem: +1-805-447-6979
Shen Le: +86 (10) 5960-8600 (China media)